Evaluation of nuclear imaging potential and photodynamic therapy efficacy of symmetrical and asymmetrical zinc phthalocyanines

Basit Öğe Kaydı
dc.contributor.authorOcakoglu, Kasim
dc.contributor.authorEr, Ozge
dc.contributor.authorErsoz, Onur Alp
dc.contributor.authorLambrecht, Fatma Yurt
dc.contributor.authorInce, Mine
dc.contributor.authorKayabasi, Cagla
dc.contributor.authorGunduz, Cumhur
dc.date.accessioned2019-10-27T23:09:45Z
dc.date.available2019-10-27T23:09:45Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractPhotodynamic therapy (PDT) is a medical treatment for the removal of target tissues involving the delivery of a photosensitizer agent followed by irradiation with visible light. In the present study, symmetric Zn(II)Pc 1 and asymmetrically substituted Zn(II)Pc 2 were synthesized and examined multifunctional agents for tumor nuclear imaging, and PDT potential. The Zn(II)Pc 1 and Zn(II)Pc 2 were radiolabeled with I-131 with high efficiency (93.4 +/- 1.6% and 91.4 +/- 1.6%, respectively). The results of the biodistribution study showed that radiolabeled Zn(II)Pc 1 had high uptake on lung, large intestine, ovary and pancreas. However, the uptake of radiolabeled Zn(II)Pc 2 was statically significant in pancreas and intestine. In PDT studies, EMT6/P (mouse mammary cell) and HeLa (cervical adenocarcinoma cell) with Zn(II)Pc 1 and Zn(II)Pc 2 were exposed to red light at the doses of 10-30 J/cm(2). Although PDT activity of Zn(II)Pc 2 in HeLa cell line was determined, Zn(II)Pc 1 showed no phototoxic effect in both cell lines. In conclusion, radiolabeled Zn(II)Pc 1 might be a promising imaging agent for the lung, the ovary pancreas, and the colon tumors. However, radiolabeled Zn(II)Pc 2 might be a promising nuclear imaging agent for the colon and the pancreas tumors and promising PDT agent for cervical tumors. (C) 2016 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey, TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [112T565]en_US
dc.description.sponsorshipThe authors gratefully acknowledge the financial support by the Scientific and Technological Research Council of Turkey, TUBITAK (Grant no: 112T565).en_US
dc.identifier.doi10.1016/j.jddst.2016.04.005
dc.identifier.endpage169en_US
dc.identifier.issn1773-2247
dc.identifier.issn1773-2247en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage164en_US
dc.identifier.urihttps://doi.org/10.1016/j.jddst.2016.04.005
dc.identifier.urihttps://hdl.handle.net/11454/52736
dc.identifier.volume33en_US
dc.identifier.wosWOS:000378453600018en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofJournal of Drug Delivery Science and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPhotodynamic therapyen_US
dc.subjectCanceren_US
dc.subjectBiodistributionen_US
dc.subjectI-131en_US
dc.subjectRadiolabelingen_US
dc.subjectPhthalocyanineen_US
dc.titleEvaluation of nuclear imaging potential and photodynamic therapy efficacy of symmetrical and asymmetrical zinc phthalocyaninesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu